Enterprise League logo
Novus Therapeutics, Inc. Logo

Novus Therapeutics, Inc.

Irvine, United States (US) · Health and Medical

Do you work at Novus Therapeutics, Inc.?

Claim this profile to manage your company.

Verified by Enterprise League

Data quality

Complete · Accuracy

#clinical development

#biotechnology

#autoimmune diseases

#transplant

#als

#renal transplant

#islet cell transplant

#lupus nephritis

#type 1 diabetes

Novus Therapeutics, Inc. is a Health and Medical company based in Irvine, United States (US), founded in 2017, with 10-20 employees. Novus Therapeutics, Inc.'s profile is verified on Enterprise League.

Overview

Novus Therapeutics is an Irvine, California-based clinical stage biotechnology company focused on developing innovative therapies targeting the CD40L pathway.

We are dedicated to ‘One Transplant For Life’ to significantly improve both the longevity of the organ and the overall health and quality of life for transplant recipients so that a donor’s greatest gift will keep on giving.

Our lead compound, tegoprubart, an anti-CD40L antibody, offers a potentially transformative approach to managing immune responses in transplant patients, representing a significant advancement over existing treatment options. We are currently evaluating its potential in kidney, liver, and xenotransplantation.

Novus Therapeutics is committed to advancing the field of transplantation and improving patient outcomes through rigorous clinical development and scientific innovation.
Visit Official Website

Most teams do this before shortlisting


Contact Details

+1(949) 238-8090
info@eledon.com

Irvine, United States (US), 19900 MacArthur Blvd, Suite 550

Founded

2017

Company Type

Public Limited Company

Employees

10-20

Categories

Biopharma
Life Science
Biotechnology

Keywords

#clinical development

#biotechnology

#autoimmune diseases

#transplant

#als

#renal transplant

#islet cell transplant

#lupus nephritis

#type 1 diabetes

Awards

• 2026 OpenSee all

Products

Default Product Image
Tegoprubart
Biotechnology

Tegoprubart is an anti-CD40L antibody in clinical development for the prevention of organ transplant rejection. It is being evaluated in Phase 2 and Phase 1b clinical trials.

N/A

Companies teams usually look at after Novus Therapeutics, Inc.

Comparing a few options usually leads to better decisions






  • Save companies to compare later. Useful when sharing options with your team

This is how your company profile looks to others.